Biohaven CEO says drug approval is ‘monumental’ for migraine patients

62
18
Favorite

Biohaven CEO says drug approval is ‘monumental’ for migraine patients

cnbc2021-06-09

Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（18）

No comments yet

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1111279529?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-09 08:56","share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","id":"1111279529","market":"us","top_or_hot":-1,"title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","media":"cnbc","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Source Link</a>\n\n</div>\n","source":"cnbc_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BHVN","symbol_name":"Biohaven Pharmaceutical Holding Co Ltd.","start_time":0,"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","article_id":"1111279529","we_media_id":null,"thumbnails":[],"rights":{"source":"cnbc_highlight","url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.ArticleHeader-headline{#titleStyle#}a{#lv2TextColor#}.ArticleHeader-time, .Author-authorNameAndSocial a{#sourceStyle#;}","selectors":".PageBuilder-pageWrapper","filters":".ArticleHeader-eyebrow, .RelatedTags-relatedTags","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","pubTimestamp":1623200185,"sourceInfo":{"source_id":"cnbc_highlight","name":"CNBC"},"weMediaInfo":null,"summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","collect":0,"end_time":0,"defaultTopTitle":"cnbc.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"translate_title":"Biohaven首席执行官说，药物批准对偏头痛患者来说是“巨大的”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":0.9},"content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":true,"newsSizeData":{"likeSize":62,"commentSize":18,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}